/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Research To Practice | Oncology Videos · Aug 27, 2026

Experts debate the role of ctDNA in bladder cancer, questioning consolidative surgery after systemic therapy and exploring new biomarkers like uTDNA.

Effective Systemic Therapies Render Consolidative Surgery 'Overkill' in Some Bladder Cancers

For patients with locally advanced bladder cancer achieving a complete response to potent systemic therapies, experts increasingly argue against consolidative surgery. They believe such effective treatments, a stark contrast to older options, may make the risks of a major operation an unnecessary "overkill" for achieving long-term control.

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium thumbnail

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Research To Practice | Oncology Videos·3 months ago

Undetectable ctDNA in Bladder Cancer Is Not a Reliable Signal to Stop Adjuvant Therapy

While positive ctDNA is a clear indicator of disease, a negative result must be interpreted with caution. Clinical trial data shows even ctDNA-negative patients can benefit from adjuvant therapy, suggesting undetectable levels do not guarantee the absence of micrometastatic disease that still requires treatment to prevent recurrence.

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium thumbnail

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Research To Practice | Oncology Videos·3 months ago

Surgery May Still Offer a Curative Window for Advanced Bladder Cancer After Systemic Therapy

Despite excellent responses to systemic therapy in very locally advanced bladder cancer, some experts still advocate for surgery. They argue that even with a complete radiological response, a surgical intervention might represent the only "window of opportunity for cure" by eradicating residual microscopic disease and should remain a key discussion point.

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium thumbnail

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Research To Practice | Oncology Videos·3 months ago

Pairing Urinary and Circulating Tumor DNA May Enable Future Bladder Preservation Strategies

A dual-biomarker approach may revolutionize bladder cancer monitoring. Experts suggest urinary tumor DNA (utDNA) is superior for assessing the local tumor in the bladder wall, while circulating tumor DNA (ctDNA) monitors systemic disease. A negative result on both tests could provide the confidence needed to safely skip radical cystectomy.

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium thumbnail

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Research To Practice | Oncology Videos·3 months ago